1 active not recruiting, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow HER2 Positive: new trials by email Literature Review of HER2 Positive trials Research Report on HER2 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-09-18 | 2026-10-16 |
| Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 PTC+Pertuzumab, FEC-T+Pertuzumab - Breast Cancer, HER2 Positive | Phase 3 | Active not recruiting | The Netherlands Cancer Institute | 437 | 2013-12-21 | 2026-11-12 |
Breast Neoplasms (2)
Breast Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
Trastuzumab (2) · pertuzumab (2) · Carboplatin (1) · Cyclophosphamide (1) · Epirubicin (1) · Fluorouracil (1) · Paclitaxel (1) · palbociclib (1) · trastuzumab deruxtecan (1)
Daiichi Sankyo (1) · The Netherlands Cancer Institute (1)
Netherlands (1) · United States (1)
Gabe S Sonke, MD (1)